Genprex, Inc. GNPX
2.29 USD +0.20 (+9.57%)
At closeNov 11, 2026, 5:44 PM EST
2.16 -0.13 -5.58%
After hours · Nov 11, 5:44 PM ET
2.11 Day range 2.38
1.71 52-week range 110.00
- YTD
- -94.05%
- 1 year
- -97.43%
News
prnewswire.com Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium Genprex Senior Director of Quality Control & Product Development to Present Insights from Parallel AAV and Lipid-Based Development Programs Presentation to Highlight Drug Development, Manufacturing…
prnewswire.com Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress Whole-Blood Translational Analysis from Clinical Trial Patients Link TUSC2 to Mitochondrial Adaptation, Autophagy, and Protein Quality Control Expands Upon Existing REQORSA Research, Supporting…
prnewswire.com Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer Research to be Presented at the 2026 EORTC-NCI-AACR Symposium Links TROP2 Expression to Treatment Response and Explores its Role in Treatment Sensitivity Findings Suggest Low TROP2 Expression is…
prnewswire.com Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting Research explores the role of TUSC2, the therapeutic gene used in Reqorsa® Gene Therapy in mitochondrial biology and cellular aging, supporting investigation of potential applications beyond oncology…
benzinga.com Genprex Highlights New Peer-Reviewed Research In Mice Identifying Important Role For TUSC2 Tumor Suppressor Gene In Maintaining Cellular Processes Associated With Healthy Brain Aging Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities…
prnewswire.com Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging Collaborators publish new peer-reviewed study identifying sex-specific effects of TUSC2 loss on mitochondrial function, protein homeostasis, and synaptic pathways, alongside molecular similarities…
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 11.0% to $0.17 during Friday's after-market session. The company's market cap stands at $2.4 million. Lexaria Bioscience…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics…
prnewswire.com Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference Company Presentation to Highlight Lead Clinical Oncology Program and Preclinical Diabetes Program AUSTIN, Texas, Sept. 8, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:…
prnewswire.com Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials AUSTIN, Texas, Aug. 18, 2026 /PRNewswire/ -- Genprex, Inc.…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) shares increased by 108.5% to $6.59 during Monday's regular session. The market value of their outstanding shares is at $2.0 million. SL Science Holding…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 121.2% to $6.99 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 million. Supernus…
benzinga.com Genprex Partners With Roche Diagnostics To Validate Biomarkers For Patient Selection In Clinical Trials For Non-Small Cell Lung Cancer Building on promising preclinical and clinical data, this collaboration intends to refine patient identification using TROP2 as a biomarker. Genprex's initial research demonstrated that high TROP2…
prnewswire.com Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies Collaboration Advances Biomarker-Driven Patient Selection and Precision Medicine in Oncology Validation Studies Aim to Optimize Clinical Trial Patient Selection Criteria AUSTIN, Texas, Aug. 3, 2026…
benzinga.com Genprex Receives Notice Of Allowance From CIPO For Patent Covering Use Of Reqorsa Gene Therapy In Combination With Either PD-1 Or PD-L1 Antibodies For Treatment Of Lung Cancer Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")
prnewswire.com Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq® AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
prnewswire.com Genprex to Participate at BIO International Convention 2026 The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Around The World AUSTIN, Texas, June 17, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the…- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Genprex Files For Mixed Shelf Of Up To $250M https://www.sec.gov/Archives/edgar/data/1595248/000143774926019760/gnpx20260518_s3.htm
prnewswire.com Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy Published at the 2026 ASCO Annual Meeting Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Survival in Non-Small Cell Lung Cancer Patients Identified Biomarkers May Predict Patient Response,…- benzinga.com Genprex Showcases Positive Preclinical Data On Its Diabetes Gene Therapy Drug Candidate At 2026 American Society Of Gene And Cell Therapy Annual Meeting Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced…
prnewswire.com Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, May 14, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a…
benzinga.com Genprex Q1 EPS $(0.64) Up From $(13.00) YoY Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.64) per share. This is a 95.08 percent increase over losses of $(13.00) per share from the same period last year.
benzinga.com Top 3 Health Care Stocks That Are Set To Fly In Q2 The health care sector has oversold stocks with RSI below 30, presenting an opportunity for traders to buy undervalued companies.
benzinga.com Israel Patent Office Grants Genprex Patent Covering Use Of Reqorsa Gene Therapy In Combination With PD-1 Antibodies For Treatment Of Cancer Strengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene…
prnewswire.com Genprex Receives Patent Grant from The Israel Patent Office for the Combination of Reqorsa® Gene Therapy and PD-1 Antibodies to Treat Cancer Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas, April 30, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage…
prnewswire.com Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Texas, April 28, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a…
prnewswire.com Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for…
prnewswire.com Genprex Signs Sponsored Research Agreement to Study Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentially Predicting Patient Response to REQORSA Treatment Demonstrates Commitment to Tailored Treatment…
benzinga.com Genprex Research Collaborators Presents Preclinical Data From Studies Of Lead Drug Candidate, Reqorsa Gene Therapy For Treatment Of Lung Cancer At 2026 AACR Annual Meeting TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell…
prnewswire.com Genprex Collaborators Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apoptosis and Decreased Tumor Volume in ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer Cell…
defenseworld.net Cullinan Therapeutics (NASDAQ:CGEM) versus Genprex (NASDAQ:GNPX) Head to Head Comparison Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the…
benzinga.com Top Ranking Stock Picker From Congress Is Back Buying Small Cap Stocks Again: Here Are The Tickers A Congress member continues to buy small cap stocks. Here's the latest names added to his investment portfolio in March 2026.
defenseworld.net Genprex (GNPX) Expected to Announce Quarterly Earnings on Friday Genprex (NASDAQ: GNPX - Get Free Report) will likely be issuing its resultson Friday, March 27th. Analysts expect the company to announce earnings of ($13.00) per share for the quarter. Genprex Price…
prnewswire.com Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2026 AACR Annual Meeting Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therapy REQORSA is a Potential Treatment for ALK-EML4 Positive Translocated Non-Small Cell Lung Cancer…
benzinga.com Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying A member of Congress is buying stock in two small cap companies in 2026. Here's the stocks and why investors should be watching.- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com Genprex Says Japanese Patent Office Issues Favourable Appeal Decision To Grant Patent Claiming Use Of Reqorsa Gene Therapy In Combination With PD-L1 Antibodies To Treat Cancer Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq®
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of A Republican U.S. Representative made multiple trades in 2025, including Cracker Barrel and a little-known gene therapy firm.- benzinga.com Genprex Announces Clinical Program Update On GPX-002 Diabetes Gene Therapy Candidate Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Genprex Announces Preliminary in Vivo Preclinical Proof-of-concept Data for GPX-002 Diabetes Gene Therapy Drug Candidate, in a Non-human Primate Model and Mouse Model of Type 2 Diabetes Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human PrimatesGPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose…
benzinga.com Move Over, Pelosi: This Congress Member Posted 2025's Best Market Return With A 52% Gain The list of the top 10 members of Congress for 2025 investment portfolio gains. Where did Marjorie Taylor Greene rank and how close was Nancy Pelosi to the Top 10?- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of A congressman bought shares of a small cap company recently. Here's a look at the stock and why it's drawing attention.- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session